Does the media refer more to BBIO or RVMD?

In the previous week, Revolution Medicines had 10 more articles in the media than BridgeBio Pharma. MarketBeat recorded 14 mentions for Revolution Medicines and 4 mentions for BridgeBio Pharma. Revolution Medicines' average media sentiment score of 0.57 beat BridgeBio Pharma's score of 0.51 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALNY or BBIO?

In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than BridgeBio Pharma. MarketBeat recorded 7 mentions for Alnylam Pharmaceuticals and 4 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.51 beat Alnylam Pharmaceuticals' score of 0.19 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, BIIB or BBIO?

Biogen has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.29 $1.29B $5.65 39.02 BridgeBio Pharma $502.08M 26.11 -$724.93M -$3.57 N/A

Does the media refer more to BIIB or BBIO?

In the previous week, Biogen had 4 more articles in the media than BridgeBio Pharma. MarketBeat recorded 8 mentions for Biogen and 4 mentions for BridgeBio Pharma. Biogen's average media sentiment score of 1.02 beat BridgeBio Pharma's score of 0.51 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BBIO or ROIV?

In the previous week, BridgeBio Pharma had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 4 mentions for BridgeBio Pharma and 3 mentions for Roivant Sciences. BridgeBio Pharma's average media sentiment score of 0.51 beat Roivant Sciences' score of -0.54 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Is BBIO or INSM more profitable?

Insmed has a net margin of -76.94% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets BridgeBio Pharma -97.03% N/A -61.19% Insmed -76.94% -123.94% -44.30%

Does the media prefer BBIO or INSM?

In the previous week, Insmed had 1 more articles in the media than BridgeBio Pharma. MarketBeat recorded 5 mentions for Insmed and 4 mentions for BridgeBio Pharma. Insmed's average media sentiment score of 0.59 beat BridgeBio Pharma's score of 0.51 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BridgeBio Pharma (BBIO) Competitors

$67.25 +0.34 (+0.51%)

Closing price 04:00 PM Eastern

Extended Trading

$67.51 +0.26 (+0.39%)

As of 07:17 PM Eastern

Compare

BBIO vs. RVMD, ALNY, BIIB, ROIV, and INSM

Should you buy BridgeBio Pharma stock or one of its competitors? BridgeBio Pharma's main competitors and comparable companies include Revolution Medicines (RVMD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Roivant Sciences (ROIV), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BridgeBio Pharma compare to Revolution Medicines?

BridgeBio Pharma (NASDAQ:BBIO) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Revolution Medicines had 10 more articles in the media than BridgeBio Pharma. MarketBeat recorded 14 mentions for Revolution Medicines and 4 mentions for BridgeBio Pharma. Revolution Medicines' average media sentiment score of 0.57 beat BridgeBio Pharma's score of 0.51 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma currently has a consensus target price of $102.61, suggesting a potential upside of 53.00%. Revolution Medicines has a consensus target price of $234.33, suggesting a potential upside of 13.53%. Given BridgeBio Pharma's higher probable upside, equities research analysts clearly believe BridgeBio Pharma is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	2.96

BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BridgeBio Pharma has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.11	-$724.93M	-$3.57	N/A
Revolution Medicines	$11.58M	3,820.32	-$1.13B	-$8.82	N/A

Revolution Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Revolution Medicines	N/A	-88.20%	-57.85%

Summary

BridgeBio Pharma and Revolution Medicines tied by winning 8 of the 16 factors compared between the two stocks.

How does BridgeBio Pharma compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Alnylam Pharmaceuticals has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Alnylam Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.01	$313.75M	$5.38	41.31
BridgeBio Pharma	$502.08M	26.11	-$724.93M	-$3.57	N/A

Alnylam Pharmaceuticals currently has a consensus price target of $366.90, indicating a potential upside of 65.10%. BridgeBio Pharma has a consensus price target of $102.61, indicating a potential upside of 53.00%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Alnylam Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Alnylam Pharmaceuticals has a net margin of 15.26% compared to BridgeBio Pharma's net margin of -97.03%. Alnylam Pharmaceuticals' return on equity of 84.93% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
BridgeBio Pharma	-97.03%	N/A	-61.19%

In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than BridgeBio Pharma. MarketBeat recorded 7 mentions for Alnylam Pharmaceuticals and 4 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.51 beat Alnylam Pharmaceuticals' score of 0.19 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats BridgeBio Pharma on 11 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Biogen?

Biogen (NASDAQ:BIIB) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Biogen has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.29	$1.29B	$5.65	39.02
BridgeBio Pharma	$502.08M	26.11	-$724.93M	-$3.57	N/A

Biogen has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

In the previous week, Biogen had 4 more articles in the media than BridgeBio Pharma. MarketBeat recorded 8 mentions for Biogen and 4 mentions for BridgeBio Pharma. Biogen's average media sentiment score of 1.02 beat BridgeBio Pharma's score of 0.51 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen currently has a consensus price target of $230.14, suggesting a potential upside of 4.40%. BridgeBio Pharma has a consensus price target of $102.61, suggesting a potential upside of 53.00%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Biogen has a net margin of 8.32% compared to BridgeBio Pharma's net margin of -97.03%. Biogen's return on equity of 11.18% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
BridgeBio Pharma	-97.03%	N/A	-61.19%

87.9% of Biogen shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Biogen beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Roivant Sciences?

BridgeBio Pharma (NASDAQ:BBIO) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Roivant Sciences has lower revenue, but higher earnings than BridgeBio Pharma. Roivant Sciences is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.11	-$724.93M	-$3.57	N/A
Roivant Sciences	$8.26M	3,105.45	-$299.77M	-$0.53	N/A

BridgeBio Pharma currently has a consensus price target of $102.61, indicating a potential upside of 53.00%. Roivant Sciences has a consensus price target of $45.64, indicating a potential upside of 28.51%. Given BridgeBio Pharma's higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 8.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BridgeBio Pharma has a net margin of -97.03% compared to Roivant Sciences' net margin of -3,534.96%. BridgeBio Pharma's return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

In the previous week, BridgeBio Pharma had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 4 mentions for BridgeBio Pharma and 3 mentions for Roivant Sciences. BridgeBio Pharma's average media sentiment score of 0.51 beat Roivant Sciences' score of -0.54 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

BridgeBio Pharma beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Insmed?

BridgeBio Pharma (NASDAQ:BBIO) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BridgeBio Pharma has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.11	-$724.93M	-$3.57	N/A
Insmed	$606.42M	38.99	-$1.28B	-$4.11	N/A

In the previous week, Insmed had 1 more articles in the media than BridgeBio Pharma. MarketBeat recorded 5 mentions for Insmed and 4 mentions for BridgeBio Pharma. Insmed's average media sentiment score of 0.59 beat BridgeBio Pharma's score of 0.51 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Insmed has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

BridgeBio Pharma presently has a consensus price target of $102.61, indicating a potential upside of 53.00%. Insmed has a consensus price target of $200.57, indicating a potential upside of 85.26%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Insmed has a net margin of -76.94% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Insmed	-76.94%	-123.94%	-44.30%

Summary

Insmed beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks.

Get BridgeBio Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBIO vs. The Competition

Export

Metric	BridgeBio Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.15B	$3.84B	$7.09B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-18.84	12.99	274.61	26.05
Price / Sales	26.18	1,288.54	600.52	89.39
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	-6.24	16.63	10.92	6.31
Net Income	-$724.93M	-$22.67M	$3.50B	$361.43M
7 Day Performance	2.56%	-3.05%	-2.11%	-1.67%
1 Month Performance	-12.09%	-10.75%	-6.34%	-3.94%
1 Year Performance	26.22%	21.11%	8.81%	2.77%

BridgeBio Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBIO BridgeBio Pharma	3.097 of 5 stars	$67.25 +0.5%	$102.61 +52.6%	+25.1%	$13.15B	$502.08M	N/A	839
RVMD Revolution Medicines	3.0481 of 5 stars	$192.76 +0.9%	$228.21 +18.4%	+349.0%	$40.93B	$11.58M	N/A	883	Insider Trade Analyst Revision
ALNY Alnylam Pharmaceuticals	3.9166 of 5 stars	$244.32 +2.0%	$367.20 +50.3%	-49.8%	$32.06B	$3.71B	45.41	2,770	Analyst Forecast
BIIB Biogen	3.0438 of 5 stars	$219.07 +1.7%	$230.14 +5.1%	+44.5%	$31.84B	$9.89B	38.77	7,500	Trending News
ROIV Roivant Sciences	2.6295 of 5 stars	$38.99 -2.0%	$45.64 +17.0%	+125.4%	$28.73B	$8.26M	N/A	721

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBIO) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Pharma (BBIO) Competitors

BBIO vs. RVMD, ALNY, BIIB, ROIV, and INSM

How does BridgeBio Pharma compare to Revolution Medicines?

Summary

How does BridgeBio Pharma compare to Alnylam Pharmaceuticals?

Summary

How does BridgeBio Pharma compare to Biogen?

Summary

How does BridgeBio Pharma compare to Roivant Sciences?

Summary

How does BridgeBio Pharma compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Pharma (BBIO) Competitors

BBIO vs. RVMD, ALNY, BIIB, ROIV, and INSM

How does BridgeBio Pharma compare to Revolution Medicines?

Does the media refer more to BBIO or RVMD?

Do analysts rate BBIO or RVMD?

Which has more volatility and risk, BBIO or RVMD?

Do institutionals and insiders have more ownership in BBIO or RVMD?

Which has stronger valuation & earnings, BBIO or RVMD?

Is BBIO or RVMD more profitable?

Summary

How does BridgeBio Pharma compare to Alnylam Pharmaceuticals?

Which has more risk & volatility, ALNY or BBIO?

Which has better valuation & earnings, ALNY or BBIO?

Do analysts prefer ALNY or BBIO?

Is ALNY or BBIO more profitable?

Does the media favor ALNY or BBIO?

Do institutionals and insiders have more ownership in ALNY or BBIO?

Summary

How does BridgeBio Pharma compare to Biogen?

Which has higher earnings and valuation, BIIB or BBIO?

Which has more risk & volatility, BIIB or BBIO?

Does the media refer more to BIIB or BBIO?

Do analysts prefer BIIB or BBIO?

Is BIIB or BBIO more profitable?

Do insiders & institutionals hold more shares of BIIB or BBIO?

Summary

How does BridgeBio Pharma compare to Roivant Sciences?

Which has more risk & volatility, BBIO or ROIV?

Which has higher earnings and valuation, BBIO or ROIV?

Do analysts prefer BBIO or ROIV?

Do institutionals & insiders believe in BBIO or ROIV?

Is BBIO or ROIV more profitable?

Does the media refer more to BBIO or ROIV?

Summary

How does BridgeBio Pharma compare to Insmed?

Do insiders & institutionals believe in BBIO or INSM?

Which has better earnings & valuation, BBIO or INSM?

Does the media prefer BBIO or INSM?

Which has more volatility and risk, BBIO or INSM?

Do analysts recommend BBIO or INSM?

Is BBIO or INSM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools